The Persian Bipolar Spectrum Diagnostic Scale and Mood Disorder Questionnaire in Screening the Patients with Bipolar Disorder

Department of Psychiatry, Iran University of Medical Sciences, Tehran, Iran.
Archives of Iranian medicine (Impact Factor: 1.11). 02/2009; 12(1):41-7.
Source: PubMed


Considering the difficulties in diagnosing bipolar disorder in clinical practice and lack of needed screening instruments in Persian language, the present study aimed at assessing sensitivity, specificity, and predictive values for the Persian Bipolar Spectrum Diagnostic Scale.
The study was conducted in a university-affiliated hospital in Tehran, Iran, in a sample of 181 consecutive outpatients aged 18-65 years. The used instruments were the Structured Clinical Interview for DSM-IV axis I disorders, the Persian Bipolar Spectrum Diagnostic Scale, the Persian Mood Disorder Questionnaire, and the Scale to Assess Unawareness of Mental Disorder.
Most patients were males (58%) and had bipolar I disorder (57%). Other bipolar disorders and major depressive disorder were diagnosed as 5.5% and 21%, respectively. Test-retest of the Persian Bipolar Spectrum Diagnostic Scale and Mood Disorder Questionnaire demonstrated a good reliability for both. The sensitivity, specificity, and positive and negative predictive values of the Persian Bipolar Spectrum Diagnostic Scale at the score of 14, were 0.52, 0.79, 0.81, and 0.49, respectively. The sensitivity and specificity of the parallel application of the Persian Bipolar Spectrum Diagnostic Scale and Mood Disorder Questionnaire were 0.76 and 0.67, respectively.
The Persian Bipolar Spectrum Diagnostic Scale and Mood Disorder Questionnaire are useful in screening patients with bipolar disorder in clinical psychiatric settings. Parallel use of both tests seems more effective than either alone.

Download full-text


Available from: Amir Shabani
  • Source
    • "Six hundred medical students were enrolled in this study from April 2010 to May 2012. The Persian version of Mood Disorder Questionnaire (P-MDQ) (Das et al., 2005) and the Persian and validated version of Bipolar Spectrum Diagnostic Scale (P-BSDS) were exploited to screen bipolar spectrum disorders (Shabani et al., 2009). The psychometric properties of the Persian version have also been assessed in previous studies (Nassir Ghaemi et al., 2005). "

    Full-text · Article · Jun 2014
  • Source
    • "The prevalence of bipolar subtypes in our sample was in accordance with the literature [36] [37] [38] [39] [40]. The global sensitivity of the MDQ (63.7%) was also close to the sensitivity reported by Hirschfeld et al [12] in psychiatric adult outpatients and by other authors in different countries [13] [14] [15] [16] [17] [18] [19] [20] [21]. In agreement with previous studies [14] [21] [26] [28] [32], MDQ sensitivity was higher for BD I (79.41%) than for BD II (57.80%) or BD NOS (38.46%). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study assessed the psychometric performance of the Mood Disorder Questionnaire (MDQ) and its modified MDQ7 version, to screen for bipolar disorders (BD) in depressive inpatients according to depression severity, number of current axis I psychiatric comorbidities and suicidal behavior disorders. Depressed adult inpatients (n=195) were consecutively enrolled. Psychiatric diagnoses were made using the standardized DSM-IV-TR structured interview MINI 5.0.0 and medical case notes. Depression severity was assessed with the Beck Depression Inventory and the Hamilton Depression Scale. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each MDQ version were evaluated in the whole sample and according to depression severity, current axis I psychiatric comorbidities and suicidal behavior. The occurrence and the number of axis I disorders affected performance of both versions. Among depressed patients with two or more comorbidities, PPV and NPV of the MDQ were 65% and 80%, respectively, and they were respectively 56.2% and 87.9% with MDQ7. Current suicidal behavior disorders also dramatically reduced the PPV of MDQ (from 81.2% to 63.3%) and MDQ7 (from 72.2% to 52.6%) but the NPV remained above 80%. The performance of both versions of the MDQ tended to improve with the severity of depression. The MDQ is not a suitable screening instrument to diagnose BD in subjects with a complex major depressive episode and/or a current history of suicidal behavior. Nevertheless MDQ particularly in its modified version may be useful for ruling out the presence of BD among these complex patients.
    Full-text · Article · Feb 2014 · Comprehensive psychiatry
  • Source
    • "The other study, which involved 1100 outpatients, showed that the BSDS had a high negative but a low positive prognostic value. These data cast doubt on the possibility of using the BSDS to screen for BD (Shabani et al., 2009; Zimmerman et al., 2009). The HCL-32 self-questionnaire has been specifically developed for the detection of hypomania symptoms (Angst et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: There are no validated screening tools for Bipolar Disorder (BD) in Russia. To validate the Russian version of the HCL-32 for the detection of Bipolar II disorder (BD II) in patients with Recurrent Depressive Disorder (RDD). 409 patients with a current diagnosis of RDD were recruited. The diagnosis was confirmed by the validated Russian version of the Mini International Neuropsychiatric Interview (MINI). Another investigator interviewed the patients using the НСL-32 questions. The total HCL-32 score in patients with BD II was significantly higher than in patients with RDD: 18.2 (4.22) versus 10.85 (5.81) (p<0.001, d=1447). At the cut-off 14 points the sensitivity was 83.7%, specificity 71.9% (p<0.001). The Cronbach's alpha was 0.887 that means good internal consistency. The best discrimination was achieved with 8 items: decreased need for sleep, less shyness or inhibition, talkativeness, more jokes and puns, jumping thoughts distractibility, exhausting or irritating others and high and more optimistic mood. We proposed the reduced variant of the scale, that includes only these 8 variables, with sensitivity 90.5%, specificity 69.8% (AUC=0.88). The Russian version of the HCL-32 displayed a good ratio of sensitivity to specificity and can be recommended as a validated screening instrument. An 8-item version of HCL needs further research. Limitations include the specific nature of the sample, the HCL-32 assessment carried out by a psychiatrist, no comparison with other BD screening scales. The results of the 8-item version may be sample and culture dependent.
    Full-text · Article · Oct 2013 · Journal of Affective Disorders
Show more